Condition: Head and Neck Squamous Cell Carcinoma · Skin Cancer · Metastatic Head-and-neck Squamous-cell Carcinoma · Sponsor: Alpha Tau Medical LTD.
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
This description comes directly from the study's public registry record.
Tami Granot · +972-2-3737-212 · TamiG@alphatau.com
Liron Dimnik · +972-2-3737-210 · LironD@alphatau.com
Always discuss trial participation with your own doctor first.
| Sharett institute, Hadassah University Hospital - Ein-Kerem | Jerusalem, Israel | Recruiting |
| Sheba Medical Center | Ramat Gan, Israel | Recruiting |
| Tel-Aviv Medical Center | Tel Aviv, Israel | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05047094